From the helm: Amplia Therapeutics (ASX:ATX), CEO & MD, Christopher Burns & Bell Potter Analyst, Thomas Wakim.

Bell Direct
March 20, 2026

In this episode of From the Helm, Grady is joined by Amplia Therapeutics (ASX:ATX) CEO & MD Dr Christopher Burns & Bell Potter Analyst Thomas Wakim to unpack the ongoing clinical trials for their prospective treatment drug for pancreatic cancer, and its substantial market opportunities in the US.

Weekly Wrap 10 July

Jessica Amir
July 10, 2020

Morning Bell 10 July

Jessica Amir
July 10, 2020

Morning Bell 9 July

Jessica Amir
July 9, 2020

Morning Bell 8 July

Jessica Amir
July 8, 2020

Morning Bell 7 July

Jessica Amir
July 7, 2020

Morning Bell 6 July

Jessica Amir
July 6, 2020

Weekly Wrap 3 July

Jessica Amir
July 3, 2020

Morning Bell 3 July

Jessica Amir
July 3, 2020

Morning Bell 2 July

Jessica Amir
July 2, 2020

Morning Bell 1 July

Jessica Amir
July 1, 2020